Literature DB >> 7641980

Retinoic acid provokes metaplasia of epithelium formed in vitro by adult human epidermal keratinocytes.

D Asselineau1, M Darmon.   

Abstract

A striking effect of retinoids is their ability to alter cell fate during development. The mucous metaplasia produced by treating chick embryo skin in organ culture with retinoic acid is a classical example of this property. It has been impossible so far to demonstrate that retinoids are able to provoke metaplasia of adult keratinocytes grown in vitro, although these agents have been shown to block terminal epidermal differentiation, to induce increased synthesis of mucopolysaccharides, and to induce the ectopic expression of K19 and K13 keratins. Our previous work showed that adult human epidermal keratinocytes grown on dermal equivalents at the surface of a culture medium containing physiological amounts of retinoids form a normal keratinized epidermis, while when excess retinoic acid is added to the culture medium, keratinization is prevented but stratification is not. Here we show that the distribution of tissue- and differentiation-stage-specific markers in retinoic acid-treated epithelium is similar to that of the oral mucosa. Moreover, when the excess retinoic acid is removed, a new epithelium is formed beneath the "old" one and this epithelium displays an epidermal orthokeratinized phenotype, whereas the "old" epithelium remains unchanged. This phenomenon of "partial reversibility", as well as the mutually exclusive distribution of the markers of the two alternative routes of differentiation, demonstrate that retinoic acid is indeed able to provoke metaplasia of adult epidermal keratinocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641980     DOI: 10.1046/j.1432-0436.1995.5840297.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  7 in total

1.  Normal human epidermal keratinocytes express in vitro specific molecular forms of (pro)filaggrin recognized by rheumatoid arthritis-associated antifilaggrin autoantibodies.

Authors:  E Girbal-Neuhauser; M Montézin; F Croute; M Sebbag; M Simon; J J Durieux; G Serre
Journal:  Mol Med       Date:  1997-02       Impact factor: 6.354

2.  Regulation of keratin expression by retinoids.

Authors:  Hans Törmä
Journal:  Dermatoendocrinol       Date:  2011-07-01

Review 3.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Vitamin D3 induces caspase-14 expression in psoriatic lesions and enhances caspase-14 processing in organotypic skin cultures.

Authors:  Saskia Lippens; Mark Kockx; Geertrui Denecker; Michiel Knaapen; An Verheyen; Ruben Christiaen; Erwin Tschachler; Peter Vandenabeele; Wim Declercq
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

5.  A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis.

Authors:  Aishath S Naeem; Cristina Tommasi; Christian Cole; Stuart J Brown; Yanan Zhu; Benjamin Way; Saffron A G Willis Owen; Miriam Moffatt; William O Cookson; John I Harper; Wei-Li Di; Sara J Brown; Thomas Reinheckel; Ryan F L O'Shaughnessy
Journal:  J Allergy Clin Immunol       Date:  2016-11-29       Impact factor: 10.793

6.  Transcriptional changes in organoculture of full-thickness human skin following topical application of all-trans retinoic acid.

Authors:  J M Gillbro; T Al-Bader; M Westman; M J Olsson; A Mavon
Journal:  Int J Cosmet Sci       Date:  2014-03-27       Impact factor: 2.970

7.  The Microenvironment in Barrett's Esophagus Tissue Is Characterized by High FOXP3 and RALDH2 Levels.

Authors:  Alexandra Lind; Peter D Siersema; Johannes G Kusters; Tanja Konijn; Reina E Mebius; Leo Koenderman
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.